New York, February 16, 2026, 15:16 EST — Market closed.
Thermo Fisher Scientific Inc shares ended down nearly 1% on Friday, extending a four-session slide as Wall Street headed into Monday’s market holiday. The stock last closed at $504.82. (New York Stock Exchange)
With cash trading paused, attention shifts to Tuesday’s reopen. Investors are weighing whether the pullback is routine risk-trimming or a reset in how the market prices the company’s 2026 outlook and its big acquisition push.
Thermo Fisher has fallen about 6.5% since its Feb. 10 close, with losses on four straight sessions, according to the company’s stock history. (Thermo Fisher Scientific)
Moves among life-sciences tools peers were mixed on Friday. Danaher slipped about 1.2%, while Agilent rose roughly 0.7%.
One near-term focus is financing for the pending Clario deal. Thermo Fisher said on Feb. 9 it priced a $3.8 billion offering of dollar-denominated senior notes — company bonds — across four maturities, and it intends to use net proceeds to pay part of the cash consideration for Clario. (Thermo Fisher Scientific)
A Feb. 12 SEC filing showed Thermo Fisher issued the notes and expected net proceeds of about $3.76 billion after underwriting discounts and expenses. The filing said the Clario acquisition remains subject to customary closing conditions, including regulatory approvals.
Thermo Fisher agreed in October to buy privately held clinical services provider Clario for up to $9.4 billion, widening its reach in clinical trial research and data services. Leerink Partners analyst Puneet Souda called it a move into a “more steadily growing and attractive area” than early-stage research, Reuters reported. (Reuters)
The company’s operating backdrop has also been in play. On Jan. 29, Thermo Fisher forecast 2026 adjusted profit — earnings excluding some items — of $24.22 to $24.80 per share and revenue of $46.3 billion to $47.2 billion, and flagged pressure tied to U.S. academic research funding. CEO Marc Casper told analysts the company’s assumption for academic and government customers was “similar conditions to last year.” (Reuters)
Casper has pointed to a separate tailwind: drugmakers shifting production to the United States. “There’s a very big focus on reshoring more production and activity to the U.S.,” he said at the J.P. Morgan Healthcare Conference, calling it a tailwind into 2027 and 2028. (Reuters)
But this stock has been quick to swing with sentiment. Any delay in the Clario timeline, or another leg down in research and biotech spending, would test the idea that demand steadies later in the year.
For now, macro could do the heavy lifting. Investors get minutes from the Fed’s Jan. 27-28 meeting on Wednesday, Feb. 18 at 2 p.m. ET, and the Commerce Department’s personal income and outlays report — which includes the personal consumption expenditures (PCE) price index, the Fed’s preferred inflation gauge — on Friday, Feb. 20 at 8:30 a.m. EST. (Federalreserve)
